What is more, the p53BER2 expression level is deficient in most RCC samples, which means this pathway is inhibited in kidney cancer; if we could reactivate this pathway in RCC cell lines, it might be possible to treat the RCC patients by activating the p53-p53BER2 pathway. Here, TP53 is linked to renal cell carcinoma.